Subscribe and receive the latest tech updates, startup insights, and industry trends delivered straight to your inbox.
We respect your privacy. Unsubscribe at any time.
The study found that the combination of niraparib and dostarlimab, a PD-1 inhibitor, demonstrated improved progression-free survival compared to standard-of-care chemotherapy in patients with advanced or recurrent endometrial cancer, suggesting a potential new treatment option for this patient population.